Showing results (51-60 of 113) with videos related to
Sort By:
Pageof 12
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2006
A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancerManuel Hidalgo, Jan C Buckner, Charles Erlichman, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 7, 2009
Phase I and pharmacokinetic study of trabectedin as a 1- or 3-hour infusion weekly in patients with advanced solid malignanciesBahram Forouzesh, Manuel Hidalgo, Quincy Chu, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 4, 2010
A phase I pharmacologic study of necitumumab (IMC-11F8), a fully human IgG1 monoclonal antibody directed against EGFR in patients with advanced solid malignanciesBart Kuenen, Petronella O Witteveen, Rita Ruijter, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 5, 2008
Randomized, phase II study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced soft tissue sarcomaLaurence H Baker, Eric K Rowinsky, David Mendelson, et al.British Journal of Haematology|June 20, 2014
SL-401 and SL-501, targeted therapeutics directed at the interleukin-3 receptor, inhibit the growth of leukaemic cells and stem cells in advanced phase chronic myeloid leukaemiaOlga Frolova, Juliana Benito, Chris Brooks, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2003
Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patientsShazli N Malik, Lillian L Siu, Eric K Rowinsky, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2007
A phase I and pharmacokinetic study of pemetrexed plus irinotecan in patients with advanced solid malignanciesEric K Rowinsky, Muralidhar Beeram, Lisa A Hammond, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 12, 2004
A phase I and pharmacokinetic study of Col-3 (Metastat), an oral tetracycline derivative with potent matrix metalloproteinase and antitumor propertiesSamira Syed, Chris Takimoto, Manuel Hidalgo, et al.Investigational New Drugs|March 4, 2020
Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myelomaEric K Rowinsky, Agne Paner, Jesus G Berdeja, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 5, 2003
A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignanciesBahram Forouzesh, Chris H Takimoto, Andrew Goetz, et al.Pageof 12